Professor Iain Hagan
Cell Division Group Leader
Iain is a Senior Group Leader at the Institute, running the Cell Division lab. He is passionate about the study of cell division and cell cycle control. Using sophisticated manipulation of yeast as a model system, he has defined fundamental principles of cell cycle control and division that have informed our understanding of cancer cell proliferation to refine therapeutic approaches.
About Professor Iain Hagan
After completing his PhD studies Iain Hagan went to Japan on a 4-year postdoctoral fellowship with Professor Mitsuhiro Yanagida in Kyoto University. He returned to the UK in 1993 with a Cancer Research Campaign Return Fellowship to establish a group in The University of Manchester. He continued to work in what later became the Faculty of Life Sciences at The University of Manchester, with further Cancer Research Campaign Fellowship support before moving to the Cancer Research UK Manchester Institute in 2001.
In 1999, Iain was awarded the Human Frontier Science Program 10th Anniversary Medal and in 2001 was the recipient of the BSCB Hooke Medal. Iain is currently a Senior Group Leader at the CRUK Manchester Institute. In 2009, he was elected to full membership of the European Molecular Biology Organisation (EMBO). In 2016, Iain was awarded a Wellcome Trust Investigator Award to study spatial and temporal control of mitotic commitment.
Iain is Chair of the internal Grants Committee that reviews all our grant applications. From 2021 until 2023, he was Deputy Director at the CRUK Manchester Institute.
Groups
Qualifications
- PhD in Cell Biology | 1987 | University College London & ICRF
- BSc in Biochemistry | 1984 | University College London
Interests
- Control and execution of mitosis
- Control of protein phosphatases
- Mitotic spindle
Research Projects
Publications
- A TOR (target of rapamycin) and nutritional phosphoproteome of fission yeast reveals novel targets in networks conserved in humans
- Elevated basal AMP-activated protein kinase activity sensitizes colorectal cancer cells to growth inhibition by metformin
- Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture
Why I work at CRUK MI
“The Institute is made of some fantastic people who are dedicated to their research and want to make a difference to the lives of cancer patients. It is a real pleasure and honour to work alongside these great scientists and to nurture our early career researchers.”
Visit Research Group
The inappropriate proliferation of cancer cells can arise from unchecked cell division, a failure to engage cell death pathways, or simultaneous changes in both. Understanding how the diverse cues are integrated to co-ordinate cell division and death is therefore key to understanding the biology of cancer. The Cell Division group study cell cycle controls that determine when a cell commits to the physical process of genome segregation, mitosis.
Because the regulatory networks that control cell division are highly conserved, we use both unicellular fission yeast and human cells in our investigations as the yeast work identifies core principles with which to frame questions to ask of the more complex context of human cell division. Our yeast work addresses how signals from the broad range of pathways are integrated by regulatory relays on neighbouring scaffolds on the centrosome to generate a single signal to trigger division when the time is right.
Complementary studies are asking whether similar controls operate in human cells and characterises one of the key cell cycle checkpoint molecules that determines when mitosis begins, PKMYT1.
Get in touch
https://doi.org/10.1186/s12943-024-02157-x
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
12 November 2024
Institute Authors (1)
Amaya Viros
Labs & Facilities
Genome Editing and Mouse Models
Research Group
Skin Cancer & Ageing
12 November 2024
https://doi.org/10.1186/s13045-024-01610-0
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
8 October 2024
Institute Authors (6)
Georges Lacaud, Mathew Sheridan, Michael Lie-a-ling, Liam Clayfield, Jessica Whittle, Jingru Xu
Research Group
Stem Cell Biology
8 October 2024
/wp-content/uploads/2024/11/Annual-Report-2023.pdf
2023 Annual Report
13 September 2024
13 September 2024
https://doi.org/10.1126/science.adh7954
Vitamin D regulates microbiome-dependent cancer immunity
25 April 2024
Institute Authors (1)
Evangelos Giampazolias
Research Group
Cancer Immunosurveillance
25 April 2024
https://doi.org/10.1038/s41684-024-01363-w
Streamlining mouse genome editing by integrating AAV repair template delivery and CRISPR-Cas electroporation
10 April 2024
Institute Authors (1)
Natalia Moncaut
Labs & Facilities
Genome Editing and Mouse Models
10 April 2024
https://www.biorxiv.org/content/10.1101/2023.12.13.568969v1
A novel human model to deconvolve cell-intrinsic phenotypes of genetically dysregulated pathways in lung squamous cell carcinoma
14 December 2023
Institute Authors (3)
Carlos Lopez-Garcia, Caroline Dive, Anthony Oojageer
Research Group
Translational Lung Cancer Biology
14 December 2023
Our vision for world leading cancer research in the heart of Manchester
We are a leading cancer research institute within The University of Manchester, spanning the whole spectrum of cancer research – from investigating the molecular and cellular basis of cancer, to translational research and the development of therapeutics.
Our collaborations
Bringing together internationally renowned scientists and clinicians
Scientific Advisory Board
Supported by an international Scientific Advisory Board
Careers that have a lasting impact on cancer research and patient care
We are always on the lookout for talented and motivated people to join us. Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.